With no time to lose, parents drive CMT4J gene therapy forward
In honor of Rare Disease Day (Feb. 28), we salute “citizen scientists” Jocelyn and John Duff. When Talia Duff was born, her parents realized life would be different, but still joyful. They were quickly adopted by the Down syndrome parent community and fell in love with Talia and her bright smile. But when Talia was...
The post With no time to lose, parents drive CMT4J gene therapy forward appeared first on Vector.
A gene therapy advance for muscle-wasting myotubular myopathy
For more than two decades, Alan Beggs, PhD, at Boston Children’s Hospital has explored the genetic causes of congenital myopathies, disorders that weaken children’s muscles, and investigated how the mutations lead to muscle weakness. For one life-threatening disorder, X-linked myotubular myopathy (XLMTM), the work is approaching potential payoff, in the form of a clinical gene...
The post A gene therapy advance for muscle-wasting myotubular myopathy appeared first on Vector.
Who We are
The mission of the Technology and Innovation Development Office (TIDO) to maximize the impact of Boston Children’s innovations on patient health while enhancing the research endeavor.
News and Events
FY 2015 TIDO Annual Report Released
Fiscal Year 2015 was a year of growth at TIDO. Boston Children’s executed 48 licenses, a 42 percent increase over the prior year, while the total number of executed industry research and license agreements reached 91, an increase of 17 percent over the prior year. The report highlights selected agreements, Technology Development Fund award winners, and some of our technologies available for licensing.
Updated Material Transfer Agreement (MTA) Procedures (Click here)
The new IP Policy allows for researchers to independently generate and complete certain outbound academic MTAs if specific criteria are met. In addition, we have implemented a new form for initiating inbound MTAs. Please click the link above for instructions and to download the forms.